SCHEMBL5518649

SCHEMBL5518649

COc1ccc([N+](=O)[O-])cc1NC(=S)NCC1CCC(Nc2nc(N(C)C)c3ccccc3n2)CC1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 14/20 0.54
ADRA2A P08913 13/20 0.54
NPY5R Q15761 5/20 0.50
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 1/20 0.44
HTR1A P08908 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
HTR2B P41595 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5518644 1.00 MCHR1 (0.54) MCHR1ADRA2ANPY5RALDH1A1SMN1; SMN2
SCHEMBL5528126 0.92 MCHR1 (0.57) MCHR1ADRA2ANPY5RMEN1KMT2A
SCHEMBL4027989 0.92 MCHR1 (0.57) MCHR1ADRA2ANPY5RMEN1KMT2A
SCHEMBL4030503 0.87 ADRA2A (0.51) MCHR1ADRA2ANPY5RALDH1A1SMN1; SMN2
SCHEMBL5523684 0.87 ADRA2A (0.51) MCHR1ADRA2ANPY5RALDH1A1SMN1; SMN2
SCHEMBL5524066 0.86 MCHR1 (0.56) MCHR1ADRA2ANPY5RHTR1AADRA1A
SCHEMBL4033147 0.86 MCHR1 (0.56) MCHR1ADRA2ANPY5RHTR1AADRA1A
SCHEMBL4029623 0.85 MCHR1 (0.63) MCHR1ADRA2ANPY5RALDH1A1MAPT
SCHEMBL4029620 0.85 MCHR1 (0.63) MCHR1ADRA2ANPY5RALDH1A1MAPT
SCHEMBL13793914 0.84 MCHR1 (0.65) MCHR1ADRA2ANPY5RHTR1AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US claimed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 MCHR1 1/4885ADRA2A 103/4885NPY5R 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.